CA 19-9

CA 19-9

A tumour-associated carbohydrate antigen located on the sialylated Lewis A blood group antigen (individuals who are genotypically Lewis a-b-[Lea-b-] comprise 5% of the population and cannot synthesize the antigen).

Serum levels
> 37 U/mL occur in 72–100% of patients with pancreatic cancer; 97% of those with levels > 1000 U/m; 65% of those with hepatocellular carcinoma; 20+% of those with gastric cancer; 20% of those with colorectal cancer. Because CA19-9 is also elevated in benign conditions (e.g., obstructive jaundice, liver disease, acute and chronic pancreatitis, diabetes, interstitial lung disease, collagen vascular disease, cholecystitis and cirrhosis of the liver), it is not widely used as a cancer marker. At one time it was regarded as useful in differentiating mesothelioma (in which it is negative) from various adenocarcinomas (in which it is positive).

CA 19-9 (Cancer antigen 19-9)

A tumor marker associated with pancreatic cancer.
Mentioned in: Tumor Markers
References in periodicals archive ?
The tumor markers CA 19-9 and CEA were determined by enzyme immunoassays using the Axsym system (Abbott).
Contract awarded for tests carcinoembryonic antigen (cea); ca-125, ca 19-9; ca 15-3
CA 19-9 (a marker of gastrointestinal tract), tissue polypeptide antigen (TPA), and neurone-specific enolase (NSE; a marker of small cell lung carcinoma) have been studied in pregnancy.
Ca 19-9 electrochemiluminescence test method code 576
All of the main markers in current routine use (e.g., CEA, AFP, HCG, PSA, CA 125, CA 15-3, and CA 19-9) are discussed as well as potentially useful markers for the future.
Previously, the concentration of Ca 19-9 has been shown to be increased in bladder cancer patients [3, 4].
The tumor markers carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) are frequently elevated as well.
The mean CA 125 level was 22.96[+ or -]15.5 U/mL, the mean CA 19-9 level was 71.11[+ or -]17.8 U/mL, the mean CA 15-3 level was 13.97[+ or -]13.5 U/mL, the mean CEA level 1.39[+ or -]1.09 ng/mL, and the mean AFP level was 177.32[+ or -]1.9 ng/mL.
The only routinely used serum marker for PDAC is carbohydrate antigen 19-9 (CA 19-9).
Huang and Liu conducted a meta-analysis and concluded that serum CA 19-9 plays an important role in the diagnosis of pancreatic cancer [9].
To assess whether the diagnostic efficiency of HSP70 in combination with carcinoembryonic antigen (CEA) and carbohydrate antigen (CA 19-9) was superior to that of the individual biomarkers alone, new variable models for NSCLCs were created on the basis of the equations obtained by binary logistic regression.
Level of tumor marker carbohydrate antigen 19-9 (CA 19-9) was 2792 kU/l, significantly exceeding the reference range (normal value <37-40 kU/l).